DOVONEX
Drug
LEO Pharma AS
Total Payments
$14,008
Transactions
4
Doctors
3
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2017 | $14,008 | 4 | 3 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $14,008 | 4 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| A TRIAL EVALUATING THE SAFETY AND EFFICACY OF ONCE DAILY TOPICAL TREATMENT WITH LEO 90100 AEROSOL FOAM IN ADOLESCENT SUBJECTS WITH PLAQUE PSORIASIS | LEO Pharma AS | $14,008 | 3 |
Ad
Manufacturing Companies
- LEO Pharma AS $14,008
Product Information
- Type Drug
- Total Payments $14,008
- Total Doctors 3
- Transactions 4
About DOVONEX
DOVONEX is a drug associated with $14,008 in payments to 3 healthcare providers, recorded across 4 transactions in the CMS Open Payments database. The primary manufacturer is LEO Pharma AS.
Payment data is available from 2017 to 2017. In 2017, $14,008 was paid across 4 transactions to 3 doctors.
The most common payment nature for DOVONEX is "Unspecified" ($14,008, 100.0% of total).
DOVONEX is associated with 1 research study, including "A TRIAL EVALUATING THE SAFETY AND EFFICACY OF ONCE DAILY TOPICAL TREATMENT WITH LEO 90100 AEROSOL FOAM IN ADOLESCENT SUBJECTS WITH PLAQUE PSORIASIS" ($14,008).